Roche Executing Commercially, But R&D Productivity Remains A Work In Progress
Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...
precisionmedicineonline5d
Innovent's Dovbleron Gains Approval in China for ROS1-Positive NSCLC
Innovent has submitted a second new drug application (NDA) to China's National Medical Products Administration (NMPA) seeking approval for Dovbleron as a treatment for ROS1-positive advanced NSCLC ...
FiercePharma6d
Fierce Pharma Asia—Roche, Innovent's ADC deal; Lessons from AZ's China probes; Viatris' warning letter
In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.
Pharmabiz6d
Innovent inks exclusive global license agreement with Roche to advance the development of IBI3009, a novel DLL3 targeted ADC candidate
Innovent inks exclusive global license agreement with Roche to advance the development of IBI3009, a novel DLL3 targeted ADC candidate: San Francisco, US Friday, January 3, 2025, ...